

David J Bearss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4445204/publications.pdf>

Version: 2024-02-01

45
papers

6,623
citations

147801

31
h-index

233421

45
g-index

46
all docs

46
docs citations

46
times ranked

9959
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 2115-2126.	7.0	59
2	Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 2382-2389.	7.2	124
3	Activators of PKM2 in cancer metabolism. <i>Future Medicinal Chemistry</i> , 2014, 6, 1167-1178.	2.3	39
4	Different expression of placental pyruvate kinase in normal, preeclamptic and intrauterine growth restriction pregnancies. <i>Placenta</i> , 2014, 35, 883-890.	1.5	31
5	The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. <i>Leukemia</i> , 2014, 28, 451-455.	7.2	37
6	Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response. <i>Leukemia</i> , 2014, 28, 2251-2254.	7.2	2
7	A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas. <i>Neoplasia</i> , 2014, 16, 403-412.	5.3	64
8	Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. <i>Leukemia</i> , 2014, 28, 2155-2164.	7.2	232
9	Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. <i>Oncogene</i> , 2013, 32, 5089-5100.	5.9	140
10	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. <i>Cancer Research</i> , 2013, 73, 6516-6525.	0.9	70
11	Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1142-1147.	2.8	13
12	High-Throughput Virtual Screening Identifies Novel <i>N</i> -(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9496-9508.	6.4	173
13	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	7.0	848
14	Use of a Bacteriophage Lysin to Identify a Novel Target for Antimicrobial Development. <i>PLoS ONE</i> , 2013, 8, e60754.	2.5	41
15	NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers. <i>Cancer Cell</i> , 2013, 23, 48-62.	16.8	232
16	Chemical Genetic Screen Reveals a Role for Desmosomal Adhesion in Mammary Branching Morphogenesis. <i>Journal of Biological Chemistry</i> , 2013, 288, 2261-2270.	3.4	19
17	Targeting Axl and Mer Kinases in Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1763-1773.	4.1	202
18	Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 907-912.	2.8	72

#	ARTICLE	IF	CITATIONS
19	Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. <i>Experimental Cell Research</i> , 2011, 317, 307-318.	2.6	6
20	In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. <i>Experimental Hematology</i> , 2011, 39, 14-25.	0.4	6
21	Shining the Light on Aurora-A Kinase as a Drug Target in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2012-2012.	4.1	6
22	The Pim Kinases: New Targets for Drug Development. <i>Current Drug Targets</i> , 2011, 12, 2059-2066.	2.1	54
23	Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. <i>British Journal of Cancer</i> , 2011, 105, 1563-1573.	6.4	22
24	S110, a 5-Aza-2-Deoxycytidine-Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor <i>in vivo</i> and Can Reduce Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1443-1450.	4.1	142
25	Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2882-2893.	4.1	114
26	Pdx-1-Driven Overexpression of Aurora A Kinase Induces Mild Ductal Dysplasia of Pancreatic Ducts Near Islets in Transgenic Mice. <i>Pancreas</i> , 2008, 37, e39-e44.	1.1	12
27	A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. <i>Oncogene</i> , 2007, 26, 3909-3919.	5.9	261
28	Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1764-1773.	4.1	79
29	Aurora-A over-expression in high-grade PIN lesions and prostate cancer. <i>Prostate</i> , 2005, 64, 341-346.	2.3	71
30	a-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 580-588.	4.2	28
31	Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5377-5381.	2.2	15
32	Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6140-6145.	7.1	52
33	Laminin-5 β 3A Expression in LNCaP Human Prostate Carcinoma Cells Increases Cell Migration and Tumorigenicity. <i>Neoplasia</i> , 2004, 6, 468-479.	5.3	28
34	Hydrophilic Camptothecin Analogs That Form Extremely Stable Cleavable Complexes with DNA and Topoisomerase I. <i>Cancer Research</i> , 2004, 64, 6679-6683.	0.9	24
35	TELOMEREINHIBITION ANDTELOMEREDISRUPTION AS PROCESSES FOR DRUG TARGETING. <i>Annual Review of Pharmacology and Toxicology</i> , 2003, 43, 359-379.	9.4	121
36	New drugs for patients with pancreatic cancer. <i>Current Opinion in Oncology</i> , 2002, 14, 621-627.	2.4	12

#	ARTICLE	IF	CITATIONS
37	Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c- <i>MYC</i> transcription. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11593-11598.	7.1	1,970
38	Telomeres and telomerases as drug targets. Current Opinion in Pharmacology, 2002, 2, 415-423.	3.5	137
39	Potential Mouse Tumor Model for Pre-Clinical Testing of Mage-Specific Breast Cancer Vaccines. Breast Cancer Research and Treatment, 2002, 74, 221-233.	2.5	6
40	The inefficiency of incisions of ecteinascidin 743â€™DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chemistry and Biology, 2001, 8, 1033-1049.	6.0	69
41	Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene, 2000, 19, 1114-1122.	5.9	47
42	Telomere maintenance mechanisms as a target for drug development. Oncogene, 2000, 19, 6632-6641.	5.9	70
43	Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo. Journal of Biological Chemistry, 1998, 273, 20448-20455.	3.4	188
44	A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis. Molecular and Cellular Biology, 1998, 18, 85-92.	2.3	164
45	Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12845-12850.	7.1	521